PT-141 Nasal Spray (10mg)
Technische Spezifikationen
| Reinheit (HPLC) | ≥99% (HPLC) |
| CAS-Nummer | 189691-06-3 |
| Form | White lyophilized powder |
| Lagerung | -20°C |
| Sequenz | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molekulargewicht | 1,025.21 g/mol |
| Salzform | Acetate |
| Löslichkeit | Soluble in water |
PT-141 Nasal Spray (10mg)
EUR-Listenpreis · HU, SK, CZ, PL
- Eurozone (EUR)270,00 EUR
- Ungarn (HU)270,00 EUR≈ 108 000 Ft
- Slowakei (SK)270,00 EUR
- Tschechien (CZ)270,00 EUR≈ 6 750 Kč
- Polen (PL)270,00 EUR≈ 1147,50 zł
Gleicher EUR-Listenpreis für Lieferung nach Ungarn, Slowakei, Tschechien und Polen. Abrechnung in EUR.
HUF/CZK/PLN sind indikativ aus EUR umgerechnet; die Slowakei nutzt EUR. Kurse annähernd. Abrechnung in EUR.
PT-141 — Nasenspray 10 mg — intranasale Form von PT-141 für Forschung zur schnellen nasalen Resorption. Nur RUO — ausschließlich für Laborforschung; nicht zum menschlichen Verzehr.
Ausschließlich für Laborforschung.
Nicht für den menschlichen Verzehr, tierärztliche oder diagnostische Zwecke.
From the Peptide Explorer
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Key Mechanisms
- ›MC4R agonism (central, hypothalamic)
- ›MC3R partial agonism
- ›CNS-mediated arousal pathway
- ›Dopaminergic downstream signaling
- ›Independent of vascular mechanisms
Primary Research Areas
- ›Hypoactive sexual desire
- ›Melanocortin receptor pharmacology
- ›Central arousal pathways
- ›Female sexual dysfunction
Key Research Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Overview
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Origin: Derived from Melanotan II; developed by Palatin Technologies
Mechanism of Action
- MC4R agonism (central, hypothalamic)
- MC3R partial agonism
- CNS-mediated arousal pathway
- Dopaminergic downstream signaling
- Independent of vascular mechanisms
Primary Research Areas
- Hypoactive sexual desire
- Melanocortin receptor pharmacology
- Central arousal pathways
- Female sexual dysfunction
Key Published Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
PT-141 Nasal Spray (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Forschungsspezifikationen
Synthesized for strict analytical consistency. Verified via HPLC/MS.Qualitätsstandards ansehen →
Handhabung & Lagerung
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water